Total trials
264
Active
48
Phase 3
22
Total enrollment
116,573
Pipeline matrix
Showing 8 of 8 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Methotrexate | — | — | — | — | 3 | ||
| Cyclosporin A | — | — | — | — | — | 2 | |
| Acitretin | — | — | — | — | — | 2 | |
| secukinumab | — | — | — | — | — | 1 | |
| Ixekizumab | — | — | — | — | — | 1 | |
| Allogenic expanded Natural Killer Cells | — | — | — | — | — | 1 | |
| AS01 adjuvant | — | — | — | — | — | 1 | |
| YF17D | — | — | — | — | — | 1 |
Next readouts
- 2026-04
- 2027-12
- 2027-12-31
- 2029-02-28
- 2029-05-31
Top conditions
- Diabetes Mellitus, Type 210
- Dialysis Access Malfunction8
- Knee Osteoarthritis6
- Varicose Veins6
- Hypertension5
- Stroke5
- Cardiac Arrest5
- Chronic Venous Insufficiency5
Frequently asked questions about Singapore General Hospital
- How many clinical trials does Singapore General Hospital have on ClinicalTrials.gov?
- Singapore General Hospital is listed as the lead sponsor on 264 clinical trials in ClinicalTrials.gov, 48 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Singapore General Hospital's trials are in Phase 3?
- 22 of Singapore General Hospital's trials are in Phase 3, spread across 8 active drug programs.
- What therapeutic areas does Singapore General Hospital focus on?
- Singapore General Hospital's most-studied conditions on ClinicalTrials.gov are Diabetes Mellitus, Type 2, Dialysis Access Malfunction, Knee Osteoarthritis, Varicose Veins, Hypertension.
- When are Singapore General Hospital's next clinical trial readouts?
- Singapore General Hospital has 5 upcoming primary-completion readouts tracked here; the soonest is “Integrating Allogeneic NK Cells in High-risk Advanced Stage III-IV Nasopharyngeal Cancer Patients”, expected around 2026-04.